Hola,
Are you new here?

I have an account

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

BRAINVECTORS

financed

Closed

From Brain Gene Transfer Towards Gene Therapy Pharmacological Assessment of AA...

From Brain Gene Transfer Towards Gene Therapy Pharmacological Assessment of AAV CAV and LVV "BRAINVECTORS aims devising new gene therapy(GT)-based treatments for Parkinson’s and other neurodegenerative diseases, in substitution of current systemic treatments, by delivering neurotrophic factors (GDNF) into the CNS with ne... see more

31/10/2016

CHUV

2M€

Project Budget: 2M€

Project leader

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 12 Participantes

Financing granted El organismo FP7 notifico la concesión del proyecto The day 2016-10-31 We do not have the information of the call

0% 100% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

12 Participantes

CHUV

0.00€ | Leader

UNIROMA1

N.D. | participant

IBET

N.D. | participant

UAB

N.D. | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project leader

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 2M€

participation deadline Sin fecha límite de participación.

Project description "BRAINVECTORS aims devising new gene therapy(GT)-based treatments for Parkinson’s and other neurodegenerative diseases, in substitution of current systemic treatments, by delivering neurotrophic factors (GDNF) into the CNS with new vectors derived from adeno-associated (AAV), canine adenoviruses (CAV) and lentiviruses (LV) with inducible gene expression. Although AAV, CAV and LVV are considered acceptable in terms of bio-safety, their immune response must be well characterized in order to further develop these vectors for clinical trials. Furthermore, the possibility to switch-off the expression of neurotrophic factors in case of adverse effects represents a significant pharmacological progress of the gene therapy approach for Parkinson’s disease. BRAINVECTORS will: - devise new inducible gene expression cassettes with increased sensitivity of transactivators and inducers reducing thus the dose of drugs necessary to obtain GDNF expression in brain; - characterise the immune responses induced by the components of GDNF-AAV, -CAV and -LVV in rodent models for Parkinson’s disease by using biomarker-based immunological screening. The project is based upon a network of 12 participants of public academic institutions and private non-profit organisations and SMEs in France, Germany, Italy, Netherland, Portugal, Spain, Sweden and Switzerland. Some of them are traditionally linked together in developing vectors backbones, vector production technologies and Parkinson’s animal models. Others have strong immunological background, pioneering the biomarkers-based immuno-technologies for GT vectors, and have R&D expertise/facilities on/for animal cell technologies cGMP for biopharmaceuticals. 142 p-m will be involved during 48 months in R&D and TOK activities with 72 p-m of recruited postdocs and 70 p-m of seconded staff."

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers